Albert Einstein College of Medicine

Vascarta Inc. announced that the FDA has granted Orphan Drug Designation to Vasceptor (VAS-101), a patented topical curcumin formulation for treating Sickle Cell Disease.

Genflow Biosciences has successfully progressed its SIRT6 variant patent application through the European Patent Office's Supplementary Search Report without additional questions, strengthening its intellectual property position.

• HCW Biologics' proprietary fusion protein HCW9206 demonstrates superior efficacy in generating CAR-T cells with enhanced function and persistence compared to standard methods. • Studies presented at the 2025 American Association of Immunologists meeting show HCW9206 effectively expands stem cell-like memory T cells (Tscm), which exhibit greater persistence and targeted cell killing in experimental models. • The company has established GMP manufacturing processes and filed a drug master file with the FDA, positioning HCW9206 to potentially reduce costs and improve clinical outcomes for CAR-T therapies.

A groundbreaking clinical trial demonstrates that fremanezumab, a CGRP-targeting monoclonal antibody, significantly reduces both migraine frequency and depressive symptoms in patients with comorbid conditions.

Delayed REM sleep is associated with higher levels of toxic brain proteins linked to Alzheimer's disease, with late-onset REM showing 16% more amyloid and 29% more tau protein compared to early-onset REM.

Vascarta has initiated a Phase 1 proof-of-concept study evaluating VAS-101, a novel topical curcumin formulation, in ten patients with sickle cell disease at the Foundation for Sickle Cell Disease Research in Florida.

The FDA granted accelerated approval to datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for patients with previously treated EGFR-mutated non-small cell lung cancer who have progressed on both EGFR-targeted therapies and chemotherapy.

Researchers found that tumor mutational burden (TMB) and fraction genome altered (FGA) can predict how anesthetic and analgesic drugs affect survival in cancer patients.

The NIH has developed TrialGPT, an AI algorithm designed to efficiently match patients to relevant clinical trials listed on ClinicalTrials.gov.

The TAME Trial will investigate metformin's potential to prevent age-related diseases like heart disease, cancer, and cognitive decline in healthy older adults.